Vasudha Dhar, MD
Gastroenterology · East Windsor, NJNPI 1659574770
Payments from drug & device makers
Across 845 payments — averaging $23.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$12K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Johnson & Johnson$810
- QOL Medical, LLC$603
- Takeda Pharmaceuticals U.S.A., Inc.$488
- Redhill Biopharma Inc.$477
- plus $4K from 27 others
What the payments were for
- Speaking & faculty fees$8,82045%
- Grants$200%
- Food & beverage$10,68155%
- Education$330%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 310 | $11,790 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 132 | $1,659 |
| Johnson & Johnson(2 entities) | 46 | $810 |
| QOL Medical, LLC | 31 | $603 |
| Takeda Pharmaceuticals U.S.A., Inc. | 40 | $488 |
| Redhill Biopharma Inc. | 36 | $477 |
| Bristol Myers Squibb | 36 | $459 |
| Vivus LLC | 29 | $440 |
| Phathom Pharmaceuticals, Inc. | 18 | $368 |
| Sanofi | 19 | $298 |
| Ardelyx, Inc. | 20 | $294 |
| Braintree Laboratories, Inc. | 25 | $276 |
| Ironwood Pharmaceuticals, Inc | 16 | $215 |
| Madrigal Pharmaceuticals | 18 | $206 |
| Merck | 14 | $201 |
| Pfizer | 10 | $176 |
| Intercept Pharmaceuticals, Inc. | 6 | $105 |
| E.r. Squibb & Sons, L.L.C. | 1 | $85 |
| Concordia Pharmaceuticals Inc. | 6 | $84 |
| Nestle Healthcare Nutrition Inc. | 6 | $82 |
| Lilly USA, LLC | 4 | $78 |
| Ipsen Biopharmaceuticals, Inc | 4 | $75 |
| Gilead | 4 | $57 |
| Celltrion USA Inc. | 3 | $52 |
| Echosens North America, Inc. | 2 | $28 |
| Intra-sana Laboratories | 1 | $28 |
| Alfasigma USA, Inc. | 2 | $28 |
| Novo Nordisk | 1 | $24 |
| Aimmune Therapeutics, Inc. | 1 | $17 |
| Ferring Pharmaceuticals Inc. | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Meridian Bioscience Inc. | 1 | $13 |
| AstraZeneca | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,554 in reported general payments places this provider in the 90th percentile of 701 gastroenterology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 64 | $365,012 |
| ZenpepLipase/Protease/Amylase | 22 | $130,057 |
| Humira(Cf) PenAdalimumab | 14 | $94,296 |
| XeljanzTofacitinib Citrate | 15 | $83,601 |
| MotegrityPrucalopride Succinate | 24 | $34,246 |
| Mesalamine | 37 | $34,083 |
| LinzessLinaclotide | 18 | $19,428 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 79 | $12,740 |
| Dexlansoprazole DrDexlansoprazole | 16 | $6,100 |
| Colestipol Hcl | 25 | $5,919 |
| Pantoprazole Sodium | 222 | $3,294 |
| Omeprazole | 140 | $2,418 |
| Lubiprostone | 20 | $1,994 |
| Dicyclomine Hcl | 59 | $1,882 |
| Mercaptopurine | 11 | $1,792 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $11,790 | $384,44082 claims |
| Aimmune Therapeutics, Inc.Zenpep | $17 | $130,05722 claims |
| PfizerXeljanz | $176 | $83,60115 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $488 | $34,24624 claims |
| Braintree Laboratories, Inc.Sutab | $276 | $12,74079 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 701 gastroenterology providers in New Jersey.
Other gastroenterology in East Windsor
- Kiran RaoSparta$1.3M
- Adekunle AdeotiIrvington$1.2M
- Carl WallachMorristown$766K
- Vinod RustgiNew Brunswick$697K
- Arvind TrindadeNew Brunswick$652K
- Barry KaufmanEgg Harbor Township$595K
- Promila BanerjeeStratford$522K
- Neil NagariaToms River$442K
- Zamir BrelviNewark$408K
- Adam ElfantMount Laurel$385K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.